A strategy to decrease the use of risky drugs in the elderly

Article Type
Changed
Fri, 10/05/2018 - 10:42
Display Headline
A strategy to decrease the use of risky drugs in the elderly
Article PDF
Author and Disclosure Information

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail fosnighs@summa-health.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 71(7)
Publications
Topics
Page Number
561-568
Sections
Author and Disclosure Information

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail fosnighs@summa-health.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Susan M. Fosnight, RPh, CGP, BCPS
Clinical Staff Pharmacist, Department of Pharmacy, Summa Health System, Akron, OH

Kyle R. Allen, DO
Chief, Division of Geriatric Medicine, Medical Director, Post Acute and Senior Services, Summa Health System; Associate Professor of Clinical Internal and Family Medicine, Northeastern Ohio Universities College of Medicine, Akron, OH

Carolyn M. Holder, MSN, RN, CNS
Geriatrics Coordinator, Post Acute and Senior Services, Summa Health System, Akron, OH

Susan Hazelett, MSN, RN
Research Associate, Summa Health System, Akron, OH

Address: Susan M. Fosnight, RPh, CGP, BCPS, Department of Pharmacy, Summa Health System, 525 East Market Street, Akron, OH 44304; e-mail fosnighs@summa-health.org

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Issue
Cleveland Clinic Journal of Medicine - 71(7)
Page Number
561-568
Page Number
561-568
Publications
Publications
Topics
Article Type
Display Headline
A strategy to decrease the use of risky drugs in the elderly
Display Headline
A strategy to decrease the use of risky drugs in the elderly
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media